EMAIL THIS PAGE TO A FRIEND

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

A multicenter, randomized, double-blind clinical study to evaluate the efficacy and safety of PP-501-B in correction of nasolabial folds.


PMID 25521103

Abstract

Many new brands of hyaluronic acid (HA) fillers are being produced, but comparative research on the characteristics of similar products is limited. To test the efficacy, tolerability, and safety of a new HA filler, PP-501-B (Cleviel Contour; Pacific Pharma, Seoul, Korea), which is used for correcting nasolabial folds (NLFs), and to compare the performance of PP-501-B with that of Restylane Perlane (Q-Med). A total of 103 subjects with visible NLFs were enrolled in this randomized, multicenter, patient/evaluator-blind, active-controlled, matched-pair clinical study. Each subject was injected with PP-501-B in 1 NLF and Restylane Perlane in the other. All participants were reassessed for cosmetic changes at 8, 16, and 24 weeks. Wrinkle severity was rated using the 5-point Wrinkle Severity Rating Scale (WSRS). At Week 24, the mean improvement in the WSRS compared with baseline was 1.87 ± 0.73 for the PP-501-B side and 1.92 ± 0.71 for the Restylane Perlane side. Both fillers were well tolerated, and adverse reactions were mild. The new HA filler, PP-501-B, to the market, with suitable characteristics and ample safety profiles, will widen the selection of agents for physicians and patients because the purpose, area, and depth of filler injections vary.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H7630
Hyaluronic acid sodium salt from bovine vitreous humor
H5388
Hyaluronic acid sodium salt from rooster comb, avian glycosaminoglycan polysaccharide
53747
Hyaluronic acid sodium salt from Streptococcus equi, bacterial glycosaminoglycan polysaccharide
49775
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 1,200
40583
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 8,000-15,000
94137
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 10,000-30,000
97616
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 15,000-30,000
42686
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 30,000-50,000
08185
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 50,000-70,000
75048
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 70,000-90,000
96144
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 70,000-120,000
75046
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 90,000-110,000
06742
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 120,000-350,000
75043
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 130,000-150,000
75044
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 150,000-300,000
00941
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 300,000-500,000
75574
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 500,000-750,000
53163
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 750,000-1,000,000
41897
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 1,000,000-1,250,000
80486
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 1,250,000-1,500,000
63357
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 1,500,000-1,750,000
02737
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 1,750,000-2,000,000
51967
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 2,000,000-2,200,000
73641
Hyaluronic acid sodium salt from Streptococcus equi, mol wt 2,000,000-2,400,000
H9390
Hyaluronic acid sodium salt from Streptococcus zooepidemicus, bacterial glycosaminoglycan polysaccharide